期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease 被引量：34

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease
暂未订购
导出
摘要 Nonalcoholic fatty liver disease （NAFLD） is highly prevalent and can result in nonalcoholic steatohepatitis （NASH） and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators- activated receptors （PPARs） in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPARα and PPART to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH. Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPARα and PPARγ to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH.
作者 Eric R Kallwitz Alan McLachlan Scott J Cotler
机构地区 Department of Medicine Department of Microbiology and Immunology
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第1期22-28,共7页 世界胃肠病学杂志（英文版）
关键词 Non-alcoholic fatty liver disease Peroxisome proliferators-activated receptors Insulin resiatance Metabolic syndrome Pharmacologic ligands 非酒精性脂肪肝 发病机理 治疗方法 过氧物酶体
分类号 R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献108

  • 1[1]Kleiner DE,Brunt EM,Van Natta M,Behling C,Contos MJ,Cummings OW,Ferrell LD,Liu YC,Torbenson MS,Unalp-Arida A,Yeh M,McCullough AJ,Sanyal AJ.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005;41:1313-1321
  • 2[2]Browning JD,Szczepaniak LS,Dobbins R,Nuremberg P,Horton JD,Cohen JC,Grundy SM,Hobbs HH.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity.Hepatology 2004;40:1387-1395
  • 3[3]Schwimmer JB,Deutsch R,Kahen T,Lavine JE,Stanley C,Behling C.Prevalence of fatty liver in children and adolescents.Pediatrics 2006;118:1388-1393
  • 4[4]Marchesini G,Bugianesi E,Forlani G,Cerrelli F,Lenzi M,Manini R,Natale S,Vanni E,Villanova N,Melchionda N,Rizzetto M.Nonalcoholic fatty liver,steatohepatitis,and the metabolic syndrome.Hepatology 2003;37:917-923
  • 5[5]Neuschwander-Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology 2003;37:1202-1219
  • 6[6]Angulo P.Nonalcoholic fatty liver disease.N Engl J Med 2002;346:1221-1231
  • 7[7]Adams LA,Lymp JF,St Sauver J,Sanderson SO,Lindor KD,Feldstein A,Angulo P.The natural history of nonalcoholic fatty liver disease:a population-based cohort study.Gastroenterology 2005;129:113-121
  • 8[8]Matteoni CA,Younossi ZM,Gramlich T,Boparai N,Liu YC,McCullough AJ.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology 1999;116:1413-1419
  • 9[9]Caldwell SH,Oelsner DH,Iezzoni JC,Hespenheide EE,Battle EH,DriscoU CJ.Cryptogenic cirrhosis:clinical characterization and risk factors for underlying disease.Hepatology 1999;29:664-669
  • 10[10]Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 2002;36:1349-1354

同被引文献119

引证文献34

二级引证文献172

World Journal of Gastroenterology
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部